EU panel against using Erbitux for nonsmall-cell lung cancer

07/27/2009 | Wall Street Journal, The

Merck KGaA failed to gain support from the Committee for Medicinal Products for Human Use, which is part of the European Medicines Agency, to market cancer drug Erbitux to patients with non-small-cell lung cancer. Merck asked the panel to re-examine the Erbitux data and said it might appeal the ruling.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY